Cybin’s Novel Psilocybin Topline Data: 79% Remission In Major Depression Symptoms, What’s Next? – Cybin (AMEX:CYBN)
Next-generation psychedelics biotech Cybin Inc. CYBN released the full Phase 2 trial results of its deuterated psilocybin derivative CYB003 for Major Depressive Disorder (MDD.) Although a relatively small trial, outcomes…